These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27751676)

  • 1. Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.
    Dymond AW; Howes C; Pattison C; So K; Mariani G; Savage M; Mair S; Ford G; Martin P
    Clin Ther; 2016 Nov; 38(11):2447-2458. PubMed ID: 27751676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
    Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
    Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
    Darwish M; Nunez R; Youakim JM; Robertson P
    Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism, excretion and pharmacokinetics of [
    Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
    Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass balance, metabolic disposition, and pharmacokinetics of [
    Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, absorption, metabolism, and excretion of [
    Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans.
    Xu D; Divanji P; Griffith A; Sukhun R; Cheplo K; Li J; German P
    Pharmacol Res Perspect; 2024 Oct; 12(5):e70006. PubMed ID: 39257068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
    Tiseo PJ; Perdomo CA; Friedhoff LT
    Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [
    Zhou S; Shao F; Xu Z; Wang L; Jin K; Xie L; Chen J; Liu Y; Zhang H; Ou N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):563-573. PubMed ID: 28730290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
    Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
    J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
    Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
    Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Study To Determine the Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Capivasertib in Healthy Male Participants.
    Miller C; Wild M; Zhang Z; Sommavilla R; Shanahan D; Bailey C; Gränfors M; Bragg RA; Dong J; Sidhu S; Cullberg M
    Drug Metab Dispos; 2024 Aug; 52(9):939-948. PubMed ID: 39029948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
    Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects.
    Zhang X; Fettner S; Winter E; Masjedizadeh M; Hisoire G
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):345-52. PubMed ID: 21612741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.